Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
Bonnie Ky, Mary E. Putt, Heloisa Sawaya et al. · Journal of the American College of Cardiology · 2013
Cited by 563 works. doi:10.1016/j.jacc.2013.10.061
Authors
- Bonnie Ky
- Mary E. Putt
- Heloisa Sawaya
- Benjamin C. French
- James L. Januzzi
- Igal A. Sebag
- Juan Carlos Plana
- Victor Cohen
- Jose A. Banchs
- Joseph R. Carver
- Susan E. Wiegers
- Randolph P. Martin
- Michael H. Picard
- Robert Edgardo Gerszten
- Elkan F. Halpern
- Jonathan J. Passeri
- Irene Kuter
- Marielle Scherrer‐Crosbie
References
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
- Congestive heart failure in patients treated with doxorubicin
- Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes
- Biomarkers in Heart Failure
- Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
- Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
- Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation